Scleroderma News

December 1, 2020December 1, 2020

BioInvent to Produce CAN10, Cantargia’s Antibody for Scleroderma, Under New Deal

Scleroderma News

Cantargia‘s antibody CAN10, intended to treat people with scleroderma and myocarditis, will be produced by BioInvent under the terms of a new manufacturing agreement, the two companies announced. The investigational therapy is currently ... Read more

November 24, 2020November 24, 2020

Proteins Linked to Scarring, Immune Cell Activation Found at High Levels in dcSSc

Scleroderma News

Proteins involved in scarring and the escape of immune cells from blood vessels towards nearby tissues are found at high levels in people with diffuse cutaneous systemic sclerosis (dcSSc), a ... Read more

November 19, 2020November 19, 2020

LOX Enzyme May Serve as Scleroderma Biomarker, Therapeutic Target

Scleroderma News

The molecule lysyl oxidase (LOX) plays key roles in promoting skin and lung scarring in scleroderma and may serve as a potential biomarker and therapeutic target for the disease, a ... Read more

November 17, 2020November 17, 2020

Lenabasum Eases Pulmonary Decline in dcSSc Patients on Long-term Immunosuppressants, Trial Finds

Scleroderma News

Updated results from the RESOLVE-1 Phase 3 clinical trial show that treatment with lenabasum reduces lung function decline in adults with diffuse cutaneous scleroderma (dcSSc) who are on long-term immunosuppressant therapy. “We ... Read more

November 12, 2020November 12, 2020

Long-term Ofev Safely Slows Lung Function Decline in SSc-ILD Patients, Trial Data Show

Scleroderma News

Long-term treatment with Ofev (nintedanib) safely and effectively slows lung function decline in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD), according to an early analysis of the ... Read more

November 10, 2020November 10, 2020

Ofev Slows Disease Progression in SSc-ILD, Data Shows, Supporting Therapy’s Benefits

Scleroderma News

Ofev (nintedanib) slows clinically relevant disease progression in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD), according to an exploratory analysis of the Phase 3 SENSCIS trial. These new results, ... Read more

November 5, 2020November 5, 2020

Galectin-3 Protein May Be Blood Biomarker for Scleroderma and Like Diseases

Scleroderma News

Elevated blood levels of a protein called galectin-3 can help diagnose people with rheumatic diseases that include scleroderma, rheumatoid arthritis, and systemic lupus erythematosus, a study suggests. The study, “Diagnostic Power ... Read more

November 3, 2020November 3, 2020

Genetic Profile Models Show Potential to Predict Person’s Scleroderma Risk

Scleroderma News

Genomic risk scores (GRS), which predict the likelihood of developing a condition based on a person’s genetic profile, successfully distinguished people with scleroderma from those with other immune-mediated inflammatory diseases ... Read more

October 29, 2020October 29, 2020

High Levels of S100A12 Protein May Increase Severity of Scarring, ILD, Study Suggests

Scleroderma News

Elevated blood levels of the S100A12 protein, a type of danger signal released by skin cells, may contribute to skin scarring and interstitial lung disease (ILD) in people with scleroderma, ... Read more

October 27, 2020October 27, 2020

Overall Health Benefits Found With Abatacept in dcSSc Patients After 18 Months

Scleroderma News

Treatment with abatacept led to a reduction in skin stiffening and disability, as well as better overall health, in people with early diffuse cutaneous scleroderma (dcSSc) who participated in the ... Read more

October 22, 2020October 22, 2020

Machine Learning Helps Predict Stem Cell Transplant Outcomes, Study Suggests

Scleroderma News

Using a computer-based analysis to profile gene activity in blood samples may help identify the severe scleroderma patients who are most likely to respond to a stem cell transplant, a ... Read more

October 20, 2020October 20, 2020

First Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma

Scleroderma News

A Phase 1/2 clinical trial of FCX-013, Castle Creek Biosciences‘ experimental gene therapy for moderate to severe localized scleroderma, has dosed the first participant. The study (NCT03740724), which is expected to ... Read more

October 15, 2020October 15, 2020

Stem Cell Transplant Improves Quality of Life in Scleroderma Patients, Study Indicates

Scleroderma News

Autologous hematopoietic stem cell transplant (AHSCT) — replacing patients’ damaged bone marrow with their own healthy blood stem cells —  improves health-related quality of life among people with scleroderma to ... Read more

October 13, 2020October 13, 2020

Talaris Raises $115M for Clinical Trials Testing FRC001 Cell Therapy for dcSSc

Scleroderma News

Talaris Therapeutics has raised $115 million in financing, which will be used to support the clinical development of its lead therapeutic candidate, FCR001, designed to promote immune tolerance and allow patients to ... Read more

October 8, 2020October 8, 2020

AURORA Trial of CIVI030 for Raynaud’s Due to Scleroderma Resumes Patient Enrollment

COVID-19 News, Scleroderma News

A Phase 3 trial testing iloprost, known as CIVI030, for the treatment of Raynaud’s phenomenon due to scleroderma has resumed patient enrollment, according to the therapy’s developer, CiVi Biopharma. The ... Read more